Gene Panel Market Overview
The Gene Panel Market is expanding rapidly as precision medicine, targeted genomic sequencing, hereditary disease screening, and oncology testing become increasingly integrated into clinical care. Gene panels enable laboratories to analyze multiple genes simultaneously, supporting applications ranging from cancer risk assessment and pharmacogenetics to rare-disease and carrier screening. According to Market Research Future, the market was valued at USD 3.56 billion in 2025 and is projected to reach USD 14.03 billion by 2035, registering a CAGR of 14.58% during 2026–2035.
Get
Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/6100
Market Drivers
Expanded Payer Coverage and Reimbursement
Broader reimbursement for next-generation sequencing panels is reducing financial barriers to genomic testing. Increasing coverage for oncology and hereditary disease testing is supporting greater adoption across hospitals, community oncology practices, and diagnostic laboratories.
Rising Cancer Incidence and Hereditary Screening
The increasing global cancer burden and wider adoption of hereditary cancer screening guidelines are driving demand for multi-gene panels. Gene panels can evaluate multiple clinically relevant genes in a single test, making them useful for patients with suspected hereditary cancer syndromes.
Declining NGS Costs and Higher Throughput
Advances in next-generation sequencing are reducing sequencing costs while increasing laboratory throughput. These improvements are making targeted genomic testing more accessible for routine clinical applications rather than limiting it primarily to specialized research settings.
AI-Enabled Variant Interpretation
Artificial intelligence and machine-learning technologies are increasingly being incorporated into genomic workflows. Automated variant interpretation can accelerate analysis and reporting while reducing the manual workload associated with complex sequencing datasets.
Population-Scale Genomics Programs
Government-backed genomics initiatives are expanding sequencing infrastructure and creating additional opportunities for gene panel adoption. Population genomics programs in North America, Europe, and Asia-Pacific are helping establish broader clinical and research ecosystems.
Integration of Pharmacogenomics
Growing interest in personalized prescribing is creating demand for pharmacogenomic panels that identify genetic factors influencing drug response. Integration of genomic results into clinical decision-making could create recurring demand for targeted testing.
Market Challenges
Complex Regulatory Pathways
Multi-gene diagnostic panels must satisfy regulatory and validation requirements that can vary considerably between markets. Compliance with evolving IVD regulations can increase development costs and extend commercialization timelines.
Genomic Data Privacy and Security
Gene panel testing generates highly sensitive genetic information. Increasing use of cloud-based analysis and cross-border data processing creates additional requirements for consent management, encryption, secure storage, and privacy compliance.
Reimbursement Variability
Coverage for genetic testing differs across countries, insurers, and healthcare systems. Inconsistent reimbursement can limit access to advanced gene panels, particularly in markets where genomic diagnostics are still developing.
Shortage of Genetic Counselors
The increasing volume and complexity of genomic testing creates demand for professionals who can explain test results and support clinical decision-making. Shortages of genetic counselors can create bottlenecks between testing and effective interpretation.
Variants of Uncertain Significance
The identification of variants whose clinical significance is unclear can complicate interpretation and patient communication. Laboratories must continually update databases and interpretation processes as new scientific evidence becomes available.
Browse
In-depth Market Research Report on Gene Panel Market:
https://www.marketresearchfuture.com/reports/gene-panel-market-6100
Market Segmentation
By Product & Services:
Test Kits: Test kits represented approximately 60.05% of the market in 2025 and remain the dominant product category. Ready-to-use targeted sequencing kits help laboratories streamline testing workflows and reduce assay-development requirements.
Testing Services: Testing services are projected to be the fastest-growing product category, with a CAGR of 15.23% through 2035. Outsourcing allows smaller hospitals and healthcare systems to access high-throughput genomic testing without establishing complete in-house sequencing infrastructure.
Others: Other products and services include bioinformatics software, accessories, and supporting technologies used throughout gene-panel workflows.
By Technique:
Amplicon-Based: Amplicon-based workflows held approximately 65.46% of the market in 2025. Their relatively low cost, rapid turnaround, and lower DNA-input requirements make them particularly suitable for targeted oncology testing.
Hybridization Capture: Hybridization capture is expected to expand at a CAGR of 15.16% through 2035. The technique is gaining importance for larger panels requiring broad and uniform genomic coverage.
Others: Other emerging probe-based and targeted sequencing approaches contribute to the development of the gene-panel ecosystem.
By Application:
Cancer Risk Assessment: Cancer risk assessment accounted for approximately 52.45% of the market in 2025, supported by growing use of multi-gene testing for hereditary breast, ovarian, colorectal, and prostate cancer risk.
Pharmacogenetics: Pharmacogenetics is projected to be the fastest-growing application, with a CAGR of 15.11% through 2035. Increasing interest in preemptive prescribing and drug-gene interaction analysis is supporting adoption.
Others: Other applications include rare-disease testing, carrier screening, hereditary disease assessment, and other genomic applications.
By End User:
Hospitals & Clinics: Hospitals and clinics held approximately 51.98% of the market in 2025 and represent the largest end-user segment. In-house molecular pathology capabilities support increasing use of gene panels for oncology and hereditary disease testing.
Diagnostic Laboratories: Diagnostic laboratories are projected to grow at a CAGR of 14.99% through 2035 as reference laboratories expand centralized, high-throughput sequencing services.
Others: Other end users include academic research institutions, pharmaceutical companies, biotechnology organizations, and research sponsors.
Regional Insights
North America
North America led the Gene Panel Market with approximately 38.95% of global revenue in 2025. Strong reimbursement infrastructure, high adoption of oncology gene testing, advanced molecular diagnostic capabilities, and major genomics companies support the regional market. The United States accounts for the majority of regional demand.
Europe
Europe holds the second-largest regional position, supported by national genomic medicine programs, healthcare infrastructure, and initiatives such as the EU 1+ Million Genomes Initiative. Germany, the United Kingdom, France, and other European markets are expanding genomic testing capabilities, while regulatory changes are influencing product development and commercialization.
Asia-Pacific
Asia-Pacific is the fastest-growing region, with a projected CAGR of 15.25% during 2026–2035. Government-backed genomics programs, expanding laboratory infrastructure, rising cancer burden, and increasing healthcare investment are supporting adoption. China, Japan, India, and South Korea are important contributors.
South America
South America is expected to experience strong growth as public healthcare systems and private diagnostic laboratories expand access to multi-gene cancer testing. Brazil represents a major regional market, while genomic screening initiatives are creating additional opportunities.
Middle East and Africa
The Middle East and Africa represent an emerging market for gene panels. Investments in genomic medicine centers, national genome initiatives, cancer screening, and laboratory infrastructure are supporting adoption. Saudi Arabia, the UAE, South Africa, and Egypt are among the important markets.
Key Players
Illumina, Inc.
Thermo Fisher Scientific
F. Hoffmann-La Roche AG
QIAGEN N.V.
Agilent Technologies
Bio-Rad Laboratories
BGI Genomics
Myriad Genetics
Invivoscribe, Inc.
Guardant Health
Future Outlook
The Gene Panel Market is projected to grow from USD 3.56 billion in 2025 to USD 14.03 billion by 2035, registering a CAGR of 14.58% during 2026–2035. Growth is expected to be supported by expanding reimbursement, rising cancer incidence, declining sequencing costs, AI-enabled genomic interpretation, and increasing integration of precision medicine into clinical practice.
Future development is likely to center on automated variant classification, integrated sequencing and bioinformatics platforms, and the convergence of tissue-based testing with liquid biopsy technologies. Pharmacogenomic testing and expanded newborn screening could also broaden the addressable market beyond traditional oncology applications.
The growing availability of population-scale genomic data is expected to create additional opportunities for clinical research, pharmaceutical development, and real-world evidence generation. At the same time, improving genomic data security, regulatory harmonization, and access to genetic counseling will remain important considerations as gene-panel testing becomes more widely integrated into healthcare systems.
Explore key developments shaping industry transformation:
Infrared Thermometer Market Volume
Infrared Thermometer Market Forecast
Infrared Thermometer Market Outlook
